First-line bevacizumab is hypothesized to interfere with second-line activity of the EGFR inhibitor cetuximab during the treatment of colorectal cancer (CRC). Dan Aderka, MD, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel discusses the results of the BEACON-CRC trial investigating the effect of first-line bevacizumab on second-line treatment with triplet or doublet immunochemotherapy, including immunotherapy with cetuximab, in BRAF V600E-mutant metastatic CRC (mCRC) (NCT02928224). In all 3 groups, doublet, triplet, and control, median overall survival (mOS) was lower with prior bevacizumab treatment than without first-line bevacizumab, however, this difference was not statistically significant in the doublet group. Moreover, without prior bevacizumab, there was no statistically significant difference between the mOS with doublet or triplet therapy, which was 10 months and 12.6 months respectively. More research is required to verify these findings, to determine the mechanism of bevacizumab interference, and to assess the efficacy of bevacizumab in second-line with first-line triplet therapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.